News & Views

  • New Chairman to Help Speed Products to Market
    L-R Emma Nolan, Dr Marco Giardiello, Dr Lee Tatham, Antony Odell, Professor Steve Rannard and Professor Andrew Owen

New Chairman to Help Speed Products to Market

Aug 19 2019 Read 547 Times

Tandem Nano Ltd, a University of Liverpool spin-out has appointed Antony Odell as Executive Chairman to accelerate the commercialisation of its proprietary technology to reformulate poorly soluble pharmaceuticals and chemicals. Antony has a significant track record in building successful life science businesses from early to late stage. Most recently Antony was CEO at Tissue Regenix Group plc which he led from laboratory proof of concept work to an Alternative Investment Market (AIM) listed business with significant overseas operations.

The University technology, which has been licensed into Tandem, has significant implications for optimisation of product manufacture across a broad range of market sectors from new therapy generation to novel agrochemical formulations, providing partners with tailored nanoparticles of insoluble materials. It is a result of collaboration between the research groups of Professor Andrew Owen, Department of Molecular and Clinical Pharmacology and Professor Steve Rannard, Department of Chemistry. Both Andrew and Steve are directors of the company.

Antony Odell said: “I’m delighted that Tandem has made this important first step in the commercialisation of its proprietary SDN technology which already has a significant track record of success in solving the problems of poorly soluble actives. The team at the University has developed several key commercial relationships that can now be developed further within the new company in a variety of sectors some of which have significant impact for Tandem’s strong corporate social responsibility ethic.”

Professor Andrew Owen, Academic Founder, said: “The spin-out of Tandem Nano Ltd is a resounding endorsement of the University’s cross-faculty activity that has seen new medicines transition from concept through preclinical selection, regulatory approval and first-in-human evaluation. The team will continue to drive development and understanding of new modalities to bring novel therapeutic options to patients that need them across the globe.”

Reader comments

Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.

Post a Comment




Digital Edition

International Labmate February 2020

February 2020

In This Edition Chromatography - The Purification of Crown Ether Samples by a Quaternary Solvent Flash Chromatography System - New Wettable Phase Thrives in Water - Reduced Surface Activity...

View all digital editions

Events

PITTCON 2020

Mar 01 2020 Chicago, IK, USA

CISILE 2020

Mar 04 2020 Beijing, China

Medical Fair India 2020

Mar 05 2020 New Delhi, India

China Lab 2020

Mar 11 2020 Guangzhou, China

Medtec Japan 2020

Mar 16 2020 Tokyo, Japan

View all events